Jenburkt Pharmaceuticals Limited (524731) Fair Value & Analysis
Other · IN · Market cap ₹1.7B
Fair value as of: Jul 4, 2026
From 26 valuation models · updated today
Share price −1.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹955.45 – ₹1,370 · fair‑value band ₹468.44 – ₹1,523 · the ₹1,116 price screens above the ₹718.00 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jenburkt Pharmaceuticals Limited (524731) currently trades at ₹1,116, while our model-based Fair Value estimate is ₹718.00 — implying the stock looks roughly 35.7% overvalued today. We read business quality at 57/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Jenburkt Pharmaceuticals Limited generated revenue of ₹1.1B at a net margin of 14.3%. Revenue declined 10.8% year over year. It earns a return on equity of 19.3%. Net debt stands at ₹7.8M. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Jenburkt Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical formulations primarily in India. It offers products in various therapeutic areas, such as pain management, neuropathic pain, anthelmintics, analgesics and antipyretics, anti-arthritic, anti-diabetic, anti-infective, anti-fungal, anti-malarial, anti-ulcerant/antacid, aphrodisiac, cough and cold, and muscle relaxants, as well as nutraceutical and consumer products. The company provides its products through stockists and super stockists to doctors, chemists, large government and semi-government institutions, missionary hospitals, public sector enterprises, etc. It also exports its products to approximately 13 countries. The company was founded in 1985 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Jenburkt Pharmaceuticals Limited reported revenue of ₹1.7B in FY2026 versus ₹1.2B in FY2022, a compound +8.0%/yr. Reported net income was ₹347M in FY2026, compounding +11.7%/yr from FY2022.
Is 524731 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €39.38 | +124% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Jenburkt Pharmaceuticals Limited (524731) undervalued?
What is the fair value of 524731?
What is the quality score of 524731?
What is the revenue of Jenburkt Pharmaceuticals Limited (524731)?
What is the net profit margin of 524731?
Does Jenburkt Pharmaceuticals Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.